The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa
Open accessAbstract
Serum levels of interleukin-10 (IL-10) are elevated in a proportion of patients with untreated chronic hepatitis C, and this may compromise the host immune response to the virus. The capacity for IL-10 production varies according to the genetic composition of the IL-10 locus. We examined the inheritance of 3 biallelic polymorphisms in the IL-10 gene promoter in patients with chronic hepatitis C and their association with response to treatment with interferon alfa (IFN-α). After adjusting for potential confounding variables, a highly significant relationship was found between inheritance of the IL-10 promoter −592*A and −819*T alleles or the ATA haplotype and response to IFN-α therapy (P = .016). Response to treatment was also associated with viral genotype 3a, a low viral load, and less fibrosis on liver biopsy. Following in vitro stimulation of peripheral blood mononuclear cells, the IL-10 promoter haplotypes, GCC, ACC, and ATA, were associated with high, intermediate, and low IL-10 production, respectively. These findings indicate that heterogeneity in the promoter region of the IL-10 gene has a role in determining the initial response of chronic hepatitis C to IFN-α therapy. Patients who are genetically predisposed to high IL-10 production have a poor response to IFN-α and may benefit from additional treatment strategies designed to enhance a T-helper type 1 (Th1) response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepatitis C: the clinical spectrum of disease.
Hoofnagle, J. H. (1997) · Hepatology · doi:10.1002/hep.510260703 · Cited by 765
Cited by
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Interleukin-10 Therapy—Review of a New Approach
Asadullah, K., Sterry, W., & Volk, H. D. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.2.4 · Cited by 946
van den Biggelaar, A. H., van Ree, R., Rodrigues, L. C., Lell, B., Deelder, A. M., Kremsner, P. G., & Yazdanbakhsh, M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03206-2 · Cited by 705
Genetics of susceptibitlity to human infectious disease
Cooke, G. S., & Hill, A. V. S. (2001) · Nature Reviews Genetics · doi:10.1038/35103577 · Cited by 444
Host genetic factors influence disease progression in chronic hepatitis C
Powell, E. E., Edwards-Smith, C. J., Hay, J. L., Clouston, A. D., Crawford, D. H., Shorthouse, C., Purdie, D. M., & Jonsson, J. R. (2000) · Hepatology · doi:10.1053/he.2000.6253 · Cited by 398
Self-citation
Metadata
- Authors
- Edwards-Smith, C. J., Jonsson, J. R., Purdie, D. M., Bansal, A., Shorthouse, C., & Powell, E. E.
- Venue
- Hepatology
- Published
- 1999-08
- Volume
- 30
- Issue
- 2
- Pages
- 526-530
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2016283253
- Cited by
- 404
- References
- 1
- FWCI
- 11.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. https://app.cochat.ai/papers/10.1002/hep.510300207
- The paper
- Edwards-Smith, C. J., Jonsson, J. R., Purdie, D. M., Bansal, A., Shorthouse, C., & Powell, E. E. (1999). Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology. https://doi.org/10.1002/hep.510300207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.